Cargando…
The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
The mechanism underlying tumor aggressiveness and cetuximab (CTX) resistance in KRAS-wild-type (KRAS -WT) colorectal cancer remains obscure. We here provide evidence that DDX3 promoted soft agar growth and invasiveness of KRAS-WT cells, as already confirmed in KRAS-mutated cells. Mechanistically, in...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399580/ https://www.ncbi.nlm.nih.gov/pubmed/28435452 http://dx.doi.org/10.7150/thno.18175 |
_version_ | 1783230667912380416 |
---|---|
author | Wu, De-Wei Lin, Po-Lin Wang, Lee Huang, Chi-Chou Lee, Huei |
author_facet | Wu, De-Wei Lin, Po-Lin Wang, Lee Huang, Chi-Chou Lee, Huei |
author_sort | Wu, De-Wei |
collection | PubMed |
description | The mechanism underlying tumor aggressiveness and cetuximab (CTX) resistance in KRAS-wild-type (KRAS -WT) colorectal cancer remains obscure. We here provide evidence that DDX3 promoted soft agar growth and invasiveness of KRAS-WT cells, as already confirmed in KRAS-mutated cells. Mechanistically, increased KRAS expression induced ROS production, which elevated HIF-1α and YAP1 expression. Increased HIF-1α persistently promoted DDX3 expression via a KRAS/ROS/HIF-1α feedback loop. DDX3-mediated aggressiveness and CTX resistance were regulated by the YAP1/SIX2 axis in KRAS-WT cells and further confirmed in animal models. Kaplan-Meier and Cox regression analysis indicated that DDX3, KRAS, and YAP1 expression had prognostic value for OS and RFS in KRAS-WT and KRAS-mutated tumors, but SIX2 and YAP1/SIX2 were prognostic value only in KRAS-WT patients. The observation from patients seemed to support the mechanistic action of cell and animal models. We therefore suggest that combining YAP1 inhibitors with CTX may therefore suppress DDX3-mediated tumor aggressiveness and enhance CTX sensitivity in KRAS-WT colorectal cancer. |
format | Online Article Text |
id | pubmed-5399580 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-53995802017-04-21 The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer Wu, De-Wei Lin, Po-Lin Wang, Lee Huang, Chi-Chou Lee, Huei Theranostics Research Paper The mechanism underlying tumor aggressiveness and cetuximab (CTX) resistance in KRAS-wild-type (KRAS -WT) colorectal cancer remains obscure. We here provide evidence that DDX3 promoted soft agar growth and invasiveness of KRAS-WT cells, as already confirmed in KRAS-mutated cells. Mechanistically, increased KRAS expression induced ROS production, which elevated HIF-1α and YAP1 expression. Increased HIF-1α persistently promoted DDX3 expression via a KRAS/ROS/HIF-1α feedback loop. DDX3-mediated aggressiveness and CTX resistance were regulated by the YAP1/SIX2 axis in KRAS-WT cells and further confirmed in animal models. Kaplan-Meier and Cox regression analysis indicated that DDX3, KRAS, and YAP1 expression had prognostic value for OS and RFS in KRAS-WT and KRAS-mutated tumors, but SIX2 and YAP1/SIX2 were prognostic value only in KRAS-WT patients. The observation from patients seemed to support the mechanistic action of cell and animal models. We therefore suggest that combining YAP1 inhibitors with CTX may therefore suppress DDX3-mediated tumor aggressiveness and enhance CTX sensitivity in KRAS-WT colorectal cancer. Ivyspring International Publisher 2017-02-27 /pmc/articles/PMC5399580/ /pubmed/28435452 http://dx.doi.org/10.7150/thno.18175 Text en ©Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Wu, De-Wei Lin, Po-Lin Wang, Lee Huang, Chi-Chou Lee, Huei The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer |
title | The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer |
title_full | The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer |
title_fullStr | The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer |
title_full_unstemmed | The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer |
title_short | The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer |
title_sort | yap1/six2 axis is required for ddx3-mediated tumor aggressiveness and cetuximab resistance in kras-wild-type colorectal cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399580/ https://www.ncbi.nlm.nih.gov/pubmed/28435452 http://dx.doi.org/10.7150/thno.18175 |
work_keys_str_mv | AT wudewei theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT linpolin theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT wanglee theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT huangchichou theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT leehuei theyap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT wudewei yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT linpolin yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT wanglee yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT huangchichou yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer AT leehuei yap1six2axisisrequiredforddx3mediatedtumoraggressivenessandcetuximabresistanceinkraswildtypecolorectalcancer |